On Thursday, Entrada Therapeutics shared the latest issue of its quarterly newsletter with the community, featuring updates on clinical studies for individuals living with Duchenne who are amendable to exon 44, 45, 50, and 51 skipping. While the exon 50 and 51 programs remain in earlier stages of development, the exon 44 and 45 programs continue to advance, with enrollment complete for the first two cohorts in both studies. Additional study results are expected throughout 2027.
Entrada also highlighted recent community events and shared details about upcoming opportunities to connect with them.
For more information, please read Entrada’s latest community newsletter.